Plain-English translation of NCT06414733 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new HER-2 B Cell Peptide Vaccine to see if it can help your body's immune system fight advanced cancers. The vaccine is made from antibodies and peptides that target specific proteins on cancer cells. Researchers want to find the safest and most effective dose of this treatment and understand how well it works for people with metastatic breast cancer, gastrointestinal cancer, or cancers with certain genetic markers.
Many people with advanced cancers stop responding to standard treatments or run out of options. This medication is designed to work differently—by waking up your own immune system to recognize and destroy cancer cells on its own, rather than just targeting the cancer directly.
You likely qualify if…
You likely don't qualify if…
If you enroll, you will receive doses of the vaccine at clinical visits, spaced over time according to the study schedule. Your doctor will monitor your response by checking your blood work, imaging scans, and how you feel. The trial will track any side effects and measure whether your cancer shrinks or stops growing. Participation typically involves regular follow-up visits at the cancer center to receive the treatment and undergo tests.
AI-generated summary from trial data · Jun 16, 2026 · Not medical advice
United States
Phase
Safety & dosing
Sponsor
Pravin T.P Kaumaya
Enrollment target
~42 participants
Started
January 2025
Primary completion
December 2029
Age range
18 Years and older
Last updated on clinicaltrials.gov in August 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Xin Bryan, RN
Indiana University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.